Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well dasatinib works in treating patients with chronic
lymphocytic leukemia (CLL). Dasatinib may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
National Cancer Institute (NCI) Oregon Health and Science University